ABCLAbCellera Biologics Inc.
$11.83+103% 1Y
$11.83
$2.7852 weeks$14.83
Is the price fair?
What ABCL's price assumes
AbCellera Biologics Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 36.2× revenue.
36.2
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 2.67
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 2.67
- EV / EBIToperating margin −340%: the multiple describes the denominator
- not meaningful
- Market capitalisation306.6 million shares, counted Aug 3, 2026
- $3.63B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.